-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Morgan Stanley Downgrades Galapagos (NASDAQ:GLPG) to Equal Weight
Morgan Stanley Downgrades Galapagos (NASDAQ:GLPG) to Equal Weight
Morgan Stanley cut shares of Galapagos (NASDAQ:GLPG – Get Rating) from an overweight rating to an equal weight rating in a research report sent to investors on Friday, Marketbeat reports. They currently have $61.00 price target on the biotechnology company's stock, down from their prior price target of $80.00.
A number of other equities research analysts have also recently weighed in on GLPG. Royal Bank of Canada dropped their price target on shares of Galapagos from $62.00 to $55.00 in a research report on Monday, August 8th. UBS Group lifted their price objective on shares of Galapagos from €52.00 ($53.06) to €70.00 ($71.43) and gave the company a neutral rating in a report on Thursday, May 12th. JPMorgan Chase & Co. lifted their price objective on shares of Galapagos from €60.00 ($61.22) to €65.00 ($66.33) and gave the company a neutral rating in a report on Thursday, May 12th. Finally, Jefferies Financial Group cut shares of Galapagos from a hold rating to an underperform rating in a report on Monday, July 25th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of Hold and a consensus target price of $62.75.
Get Galapagos alerts:Galapagos Trading Up 8.0 %
Shares of GLPG opened at $51.99 on Friday. Galapagos has a 1-year low of $46.41 and a 1-year high of $72.11. The firm has a 50-day simple moving average of $52.71 and a two-hundred day simple moving average of $57.46.
Galapagos (NASDAQ:GLPG – Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.79) by $0.48. Galapagos had a negative net margin of 16.90% and a negative return on equity of 3.02%. The business had revenue of $146.62 million during the quarter, compared to analysts' expectations of $95.44 million. As a group, research analysts expect that Galapagos will post -3.23 EPS for the current fiscal year.Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Calamos Advisors LLC acquired a new position in Galapagos during the 1st quarter worth approximately $655,000. Bank of America Corp DE grew its holdings in Galapagos by 346.2% during the 4th quarter. Bank of America Corp DE now owns 39,012 shares of the biotechnology company's stock worth $2,151,000 after acquiring an additional 30,269 shares in the last quarter. Prelude Capital Management LLC grew its holdings in Galapagos by 32.2% during the 1st quarter. Prelude Capital Management LLC now owns 29,760 shares of the biotechnology company's stock worth $1,846,000 after acquiring an additional 7,255 shares in the last quarter. Great Point Partners LLC grew its holdings in Galapagos by 20.0% during the 1st quarter. Great Point Partners LLC now owns 360,000 shares of the biotechnology company's stock worth $22,327,000 after acquiring an additional 60,000 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Galapagos by 11.2% during the 4th quarter. Renaissance Technologies LLC now owns 56,600 shares of the biotechnology company's stock worth $3,120,000 after acquiring an additional 5,700 shares in the last quarter. Institutional investors and hedge funds own 19.48% of the company's stock.
Galapagos Company Profile
(Get Rating)
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis.
Further Reading
- Get a free copy of the StockNews.com research report on Galapagos (GLPG)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.
Morgan Stanley cut shares of Galapagos (NASDAQ:GLPG – Get Rating) from an overweight rating to an equal weight rating in a research report sent to investors on Friday, Marketbeat reports. They currently have $61.00 price target on the biotechnology company's stock, down from their prior price target of $80.00.
据Marketbeat报道,在周五发给投资者的一份研究报告中,摩根士丹利将加拉帕戈斯(纳斯达克代码:GET)的股票评级从增持下调至持平。他们目前对这家生物技术公司的股票设定了61.00美元的目标价,低于之前80.00美元的目标价。
A number of other equities research analysts have also recently weighed in on GLPG. Royal Bank of Canada dropped their price target on shares of Galapagos from $62.00 to $55.00 in a research report on Monday, August 8th. UBS Group lifted their price objective on shares of Galapagos from €52.00 ($53.06) to €70.00 ($71.43) and gave the company a neutral rating in a report on Thursday, May 12th. JPMorgan Chase & Co. lifted their price objective on shares of Galapagos from €60.00 ($61.22) to €65.00 ($66.33) and gave the company a neutral rating in a report on Thursday, May 12th. Finally, Jefferies Financial Group cut shares of Galapagos from a hold rating to an underperform rating in a report on Monday, July 25th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of Hold and a consensus target price of $62.75.
其他一些股票研究分析师最近也加入了GLPG的行列。在8月8日星期一的一份研究报告中,加拿大皇家银行将加拉帕戈斯股票的目标价从62.00美元下调至55.00美元。瑞银集团将加拉帕戈斯股票的目标价从52.00欧元(53.06美元)上调至70.00欧元(71.43美元),并在5月12日星期四的一份报告中给予该公司中性评级。摩根大通在5月12日周四的一份报告中将加拉帕戈斯股票的目标价从60.00欧元(61.22美元)上调至65.00欧元(66.33美元),并给予该公司中性评级。最后,杰富瑞金融集团在7月25日星期一的一份报告中将加拉帕戈斯的股票评级从持有评级下调至表现不佳。一名分析师对该股的评级为卖出,五名分析师给出了持有评级,两名分析师给出了买入评级。根据MarketBeat.com的数据,该公司的共识评级为持有,共识目标价为62.75美元。
Galapagos Trading Up 8.0 %
加拉帕戈斯股市上涨8.0%
Shares of GLPG opened at $51.99 on Friday. Galapagos has a 1-year low of $46.41 and a 1-year high of $72.11. The firm has a 50-day simple moving average of $52.71 and a two-hundred day simple moving average of $57.46.
上周五,GLPG的股价开盘报51.99美元。加拉帕戈斯的一年低点为46.41美元,一年高位为72.11美元。该公司的50日简单移动均线切入位在52.71美元,200日简单移动均线切入位在57.46美元。
Institutional Inflows and Outflows
机构资金流入和流出
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Calamos Advisors LLC acquired a new position in Galapagos during the 1st quarter worth approximately $655,000. Bank of America Corp DE grew its holdings in Galapagos by 346.2% during the 4th quarter. Bank of America Corp DE now owns 39,012 shares of the biotechnology company's stock worth $2,151,000 after acquiring an additional 30,269 shares in the last quarter. Prelude Capital Management LLC grew its holdings in Galapagos by 32.2% during the 1st quarter. Prelude Capital Management LLC now owns 29,760 shares of the biotechnology company's stock worth $1,846,000 after acquiring an additional 7,255 shares in the last quarter. Great Point Partners LLC grew its holdings in Galapagos by 20.0% during the 1st quarter. Great Point Partners LLC now owns 360,000 shares of the biotechnology company's stock worth $22,327,000 after acquiring an additional 60,000 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Galapagos by 11.2% during the 4th quarter. Renaissance Technologies LLC now owns 56,600 shares of the biotechnology company's stock worth $3,120,000 after acquiring an additional 5,700 shares in the last quarter. Institutional investors and hedge funds own 19.48% of the company's stock.
机构投资者和对冲基金最近增持或减持了该公司的股份。卡拉莫斯顾问公司第一季度在加拉帕戈斯收购了一个新头寸,价值约65.5万美元。第四季度,美国银行(Bank Of America Corp)在加拉帕戈斯的持股增加了346.2%。美国银行DE现在持有39,012股生物技术公司的股票,价值2,151,000美元,此前在上个季度又购买了30,269股。第一季度,Prelude Capital Management LLC在加拉帕戈斯的持股增加了32.2%。Prelude Capital Management LLC现在拥有29,760股这家生物技术公司的股票,价值1,846,000美元,上个季度又收购了7,255股。Great Point Partners LLC在第一季度增持了20.0%的加拉帕戈斯股份。Great Point Partners LLC现在拥有360,000股这家生物技术公司的股票,价值22,327,000美元,在上个季度又购买了60,000股。最后,复兴科技有限责任公司在第四季度增持了11.2%的加拉帕戈斯股份。复兴科技有限责任公司在上个季度增持了5,700股后,现在持有这家生物技术公司56,600股股票,价值3,120,000美元。机构投资者和对冲基金持有该公司19.48%的股票。
Galapagos Company Profile
加拉帕戈斯公司简介
(Get Rating)
(获取评级)
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis.
加拉帕戈斯公司是一家综合性生物制药公司,从事各种药物的发现、开发和商业化,以满足高度未得到满足的医疗需求。其流水线产品包括非戈替尼,一种JAK1抑制剂,正处于临床试验的不同阶段,用于治疗类风湿性关节炎、克罗恩病、溃疡性结肠炎、小肠CD、瘘管性CD、强直性脊柱炎、牛皮癣关节炎和葡萄膜炎。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Galapagos (GLPG)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 免费获取StockNews.com关于加拉帕戈斯的研究报告(GLPG)
- 达顿餐厅走低通胀之路
- 这3只股票为何在9月火爆开盘
- 通货膨胀没有差别,但它的影响有差别
- 3只被降级的必备股票放在你的观察名单上
- 这是对第三季度收益报告季节的预期
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.
接受加拉帕戈斯日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对加拉帕戈斯和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧